One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: Data from a veteran cohort

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 22, Issue 7, 2010, Pages 886-894

  Breaux, Katharine ^a,b   Gadde, Susmitha ^b   Graviss, Edward A ^b,c   Rodriguez Barradas, Maria C ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

AIDS; CD4; survival; US veterans

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CORONARY ARTERY DISEASE; DEMOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENESCENCE; SURVIVAL TIME; VIRUS LOAD; VIRUS VIRULENCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CONFIDENCE INTERVALS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 77954736685     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120903499162     Document Type: Article

References (32)

1. Antiretroviral Therapy Cohort Collaboration (2007). Importance of baseline prognostic factors with increasing time since the initiation of highly active antiretroviral therapy: Collaborative analysis of cohorts in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes, 46(5), 607-615.
2. Backus, L.I., Phillips, B.R., Boothroyd, D.B., Mole, L.A., Burgess, J., Rigsby, M.O., et al. (2005). Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 39(5), 613-619.
3. Bartlett, J.A., Fath,M.J., Demasi, R., Hermes, A., Quinn, J., Mondou, E., et al. (2006). An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS, 20(16), 2051- 2064.
4. Bhavan, K.P., Kampalath, V.N., & Overton, E.T. (2008). The aging of the HIV epidemic. Current HIV/AIDS Reports, 5(3), 150-158.
5. Braithwaite, R.S., Justice, A.C., Chang, C.C., Fusco, J.S., Raffanti, S.R., Wong, J.B., et al. (2005). Estimating the proportion of patients infected with HIV who will die of comorbid diseases. American Journal of Medicine, 118(8), 890-898.
6. Braithwaite, R.S., Kozal, M.J., Chang, C.C., Roberts, M.S., Fultz, S.L., Goetz, M.B., et al. (2007). Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS, 21(12), 1579-1589.
7. Centers for Disease Control and Prevention (2009a). Morbidity and Mortality Weekly Report: Late HIV Testing-34 States, 1996-2005. Retrieved September 1, 2009, from http://www.cdc.gov/mmwr/preview/mmwr html/mm5824a2.htm.
8. Centers for Disease Control and Prevention (2009b). HIV/ AIDS Surveillance Report: Cases of HIV Infection and AIDS in the United States and Dependent Areas, 2007. Retrieved September 1, 2009, from http://www.cdc. gov/hiv/topics/surveillance/resources/reports/.
9. Crum, N.F., Riffenburgh, R.H., Wegner, S., Agan, B.K., Tasker, S.A., Spooner, K.M., et al. (2006). Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. Journal of Acquired Immune Deficiency Syndromes, 41(2), 194-200.
10. Deayton, J.R., Sabin, C.A., Johnson, M.A., Emery, V.C., Wilson, P., & Griffiths, P.D. (2004). Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet, 363(9427), 2116- 2121.
11. Dorrucci, M., Valdarchi, C., Suligoi, B., Zaccarelli, M., Sinicco, A., Giuliani, M., et al. (2004). The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. AIDS, 18(17), 2313-2318.
12. Effros, R.B., Fletcher, C.V., Gebo, K., Halter, J.B., Hazzard, W.R., Horne, F.M., et al. (2008). Aging and infectious diseases: Workshop on HIV infection and aging: What is known and future research directions. Clinical Infectious Diseases, 47(4), 542-553.
13. Egger, M., May, M., Chêne, G., Phillips, A.N., Ledergerber, B., Dabis, F., et al. (2002). Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet, 360(9327), 119-129. (Pubitemid 34786200)
14. Food and Drug Administration (2007). US Department of Health and Human Services Office of Special Health Issues: Information for patients. Drugs used in the treatment of HIV infection. Retrieved February 2, 2008, from http://www.fda.gov/oashi/aids/virals.html.
15. Gandhi, N.R., Skanderson, M., Gordon, K.S., Concato, J., & Justice, A.C. (2007). Delayed presentation for human immunodeficiency virus (HIV) care among veterans: A problem of access or screening? Medical Care, 45(11), 1105-1109.
16. Giordano, T.P., Gifford, A.L., White, Jr., A.C., Suarez-Almazor, M.E., Rabeneck, L., Hartman, C., et al. (2007). Retention in care: A challenge to survival with HIV infection. Clinical Infectious Diseases, 44(11), 1493-1499.
17. Graviss, E.A., Breaux, K., & Minihan, J.L. (1999). Survival of patients with HIV infections and CD4's below 100 cells/mm3; a nine year follow-up study [Abstract]. In 39th interscience conference on antimicrobial agents and chemotherapy (p. 452). Washington, DC: American Society for Microbiology.
18. Hoang, T., Goetz, M.B., Yano, E.M., Rossman, B., Anaya, H.D., & Knapp, H. (2009). The impact of integrated HIV care on patient health outcomes. Medical Care, 47(5), 560-567.
19. Hooshyar, D., Hanson, D.L., Wolfe, M., Selik, R.M., Bushkin, S.E., & McNaghten, A.D. (2007). Trends in perimortal conditions and mortality rates among HIVinfected patients. AIDS, 21(15), 2093-2100.
20. Hosmer, D.W., & Lemeshow, S. (1989). Applied logistic regression. Somerset, NJ: John Wiley.
21. Justice, A.C., Dombrowski, E., Conigliaro, J., Fultz, S.L., Gibson, D., Madenwald, T., et al. (2006a). Veterans aging cohort study (VACS) overview and description. Medical Care, 44(Suppl. 2), 13-24.
22. Justice, A.C., Erdos, J., Brandt, C., Conigliaro, J., Tierney, W., & Bryant, K. (2006b). The veterans affairs healthcare system. A unique laboratory for observational and interventional research. Medical Care, 44(Suppl. 2), 7-12.
23. Kilbourne, A.M., Justice, A.C., Rabeneck, L., Rodriguez-Barradas, M., & Weissman, S. (2001). General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. Journal of Clinical Epidemiology, 54(S1), 22-28.
24. Manfredi, R. (2002). HIV disease and advanced age: An increasing therapeutic challenge. Drugs & Aging, 19(9), 647-669.
25. Monforte, D.A., Abrams, D., Pradier, C., Weber, R., Reiss, P., Bonnet, F., et al. (2008). Data collection on Adverse Events of Anti-HIV Drugs (D:A:D) study group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS, 22(16), 2143-2145.
26. Moore, R.D., Keruly, J.C., Gebo, K.A., & Lucas, G.M. (2005). An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. Journal of Acquired Immune Deficiency Syndromes, 39(2), 195-198.
27. Nguyen, N., & Holodniy, M. (2008). HIV infection in the elderly. Clinical Interventions in Aging, 3(3), 453-472.
28. Palella, Jr., F.J., Baker, R.K., Moorman, A.C., Chmiel, J.S., Wood, K.C., Brooks, Jr., J.T., et al. (2006). Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. Journal of Acquired Immune Deficiency Syndromes, 43(1), 27-34.
29. Sackoff, J.E., Hanna, D.B., Pfeiffer, M.R., & Torian, L.V. (2006). Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Annals of Internal Medicine, 145(6), 397-406.
30. Schwarz, S., Hsu, L., Dilley, J.W., Loeb, L., & Boyd, S. (2006). Late diagnosis of HIV infection: Trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. Journal of the Acquired Immunodeficiency Syndrome, 43(4), 491-494.
31. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr, W.M. Lundgren, J.D., Neaton, J.D., Gordin, F., Abrams, D., et al. (2006). CD4- count-guided interruption of antiretroviral treatment. New England Journal of Medicine, 355(22), 2283- 2296.
32. Weis, N., Lindhardt, B.O., Kronborg, G., Hansen, A.B., Laursen, A.L., Christensen, P.B., et al. (2006). Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: A nationwide cohort study. Clinical Infectious Diseases, 42(10), 1481-1487.